Patents by Inventor Robert Sibley

Robert Sibley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pteridine derivatives as modulators of ROR gamma
    Patent number: 10450314
    Abstract: The present invention encompasses compounds of formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: October 22, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Steven Richard Brunette, Johanna Csengery, Robert Owen Hughes, Xiang Li, Robert Sibley, Michael Robert Turner, Zhaoming Xiong
  • Compounds as modulators of ROR?
    Patent number: 9598415
    Abstract: The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: March 21, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Johanna Bakonyi, Steven Richard Brunette, Delphine Collin, Robert Owen Hughes, Xiang Li, Shuang Liang, Robert Sibley, Michael Robert Turner, Lifen Wu, Qiang Zhang
  • Inhibitors of leukotriene production
    Patent number: 9573957
    Abstract: The present invention relates to aryl pyrazoles, and pharmaceutically acceptable salts thereof. The aryl pyrazoles of the present invention are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorders. The present invention also relates to pharmaceutical compositions comprising the aryl pyrazoles of the present invention, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: February 21, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Asitha Abeywardane, John Broadwater, Steven Richard Brunette, Thomas Martin Kirrane, Jr., Hossein Razavi, Robert Sibley, Lana Louise Smith Keenan, Qiang Zhang
  • 11-OXO-10,11-dihydrodibenzo[B,F][1,4]thiazepine S-oxide derivatives and their use as dopamine D2 receptor antagonists
    Patent number: 9550742
    Abstract: The disclosure includes compounds and pharmaceutically acceptable salts of Formula (I). Certain compounds and salts of Formula (I) are selective inhibitors of the Dopamine D2 receptor. The variables R1-R4, n, and L are defined herein. The disclosure also provides methods of synthesizing compounds of Formula (I) and pharmaceutical compositions containing compounds of Formula (I). Additionally the disclosure provides methods or treating patients suffering from central nervous system disorders, including Tourette's syndrome, bipolar disorder, hyperprolactinemia, tardive dyskinesia, Huntington's chorea, psychosis, depression, or schizophrenia.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: January 24, 2017
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Juan Jose Marugan, Jingbo Xiao, Marc Ferrer, Noel Terrence Southall, R. Benjamin Free, David Robert Sibley
  • Inhibitors of leukotriene production
    Patent number: 9403830
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein A1, A2, L1 and B are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: August 2, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Asitha Abeywardane, Steven Richard Brunette, Michael Jason Burke, Thomas Martin Kirrane, Jr., Chuk Chui Man, Daniel Richard Marshall, Anil Kumar Padyana, Hossein Razavi, Robert Sibley, Lana Louise Smith Keenan, Roger John Snow, Ronald John Sorcek, Hidenori Takahashi, Steven John Taylor, Michael Robert Turner, Erick Richard Roush Young, Qiang Zhang, Yunlong Zhang, Renee M. Zindell
  • 11-OXO-10,11-DIHYDRODIBENZO[B,F][1,4]THIAZEPINE S-OXIDE DERIVATIVES AND THEIR USE AS DOPAMINE D2 RECEPTOR ANTAGONISTS
    Publication number: 20160176831
    Abstract: The disclosure includes compounds and pharmaceutically acceptable salts of Formula (I). Certain compounds and salts of Formula (I) are selective inhibitors of the Dopamine D2 receptor. The variables R1-R4, n, and L are defined herein. The disclosure also provides methods of synthesizing compounds of Formula (I) and pharmaceutical compositions containing compounds of Formula (I). Additionally the disclosure provides methods or treating patients suffering from central nervous system disorders, including Tourette's syndrome, bipolar disorder, hyperprolactinemia, tardive dyskinesia, Huntington's chorea, psychosis, depression, or schizophrenia.
    Type: Application
    Filed: July 29, 2014
    Publication date: June 23, 2016
    Inventors: Juan Jose Marugan, Jingbo Xiao, Marc Ferrer, Noel Terrence Southall, R. Benjamin Free, David Robert Sibley
  • Compounds as modulators of ROR?
    Patent number: 9242989
    Abstract: The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: January 26, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Johanna Bakonyi, Steven Richard Brunette, Delphine Collin, Robert Owen Hughes, Xiang Li, Shuang Liang, Robert Sibley, Michael Robert Turner, Lifen Wu, Qiang Zhang
  • Rho kinase inhibitors
    Patent number: 9079880
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: July 14, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: John David Ginn, Daniel Richard Marshall, Robert Sibley, Ronald John Sorcek, Erick Richard Roush Young, Yunlong Zhang
  • Rho kinase inhibitors
    Patent number: 9000154
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: April 7, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Martin Kirrane, Daniel Richard Marshall, Robert Sibley, Roger John Snow, Fariba Soleymanzadeh, Ronald John Sorcek
  • Benzodioxane inhibitors of leukotriene production
    Patent number: 8946203
    Abstract: The present invention relates to compounds of formula (I): wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: February 3, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Asitha Abeywardane, Steven Richard Brunette, Michael J. Burke, Suresh R. Kapadia, Thomas Martin Kirrane, Matthew Russell Netherton, Hossein Razavi, Sonia Rodriguez, Anjan Saha, Robert Sibley, Lana Louise Smith-Keenan, Hidenori Takahashi, Michael Robert Turner, Jiang-Ping Wu, Erick Richard Roush Young, Qiang Zhang, Qing Zhang, Renee M. Zindell
  • Rho kinase inhibitors
    Patent number: 8697911
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: April 15, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Brian Nicholas Cook, Jennifer A. Kowalski, Xiang Li, Daniel Richard Marshall, Sabine Schlyer, Robert Sibley, Lana Louise Smith-Keenan, Fariba Soleymanzadeh, Ronald John Sorcek, Erick Richard Roush Young, Yunlong Zhang
  • CXCR3 receptor antagonists
    Patent number: 8450317
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 to R5, A, B, D and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: May 28, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jennifer A. Kowalski, Daniel Richard Marshall, Anthony S. Prokopowicz, III, Sabine Schlyer, Robert Sibley, Ronald John Sorcek, Di Wu, Frank Wu, Erick Richard Roush Young
  • CXCR3 receptor antagonists
    Patent number: 8362249
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 to R6, A, B, X, Y and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: April 21, 2010
    Date of Patent: January 29, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: John David Ginn, Daniel Richard Marshall, Anthony S. Prokopowicz, Sabine Schlyer, Robert Sibley, Michael Robert Turner, Di Wu, Frank Wu
  • RHO KINASE INHIBITORS
    Publication number: 20120165322
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: June 29, 2011
    Publication date: June 28, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Brian Nicholas Cook, Jennifer A. Kowalski, Xiang Li, Daniel Richard Marshall, Sabine Schlyer, Robert Sibley, Lana Louise Smith-Keenan, Fariba Soleymanzadeh, Ronald John Sorcek, Erick Richard Roush Young, Yunlong Zhang
  • Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas
    Publication number: 20120129893
    Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
    Type: Application
    Filed: January 12, 2012
    Publication date: May 24, 2012
    Inventors: Jacques DUMAS, Uday Khire, Timothy B. Lowinger, Holger Paulsen, Bernd Riedl, William J. Scott, Roger A. Smith, Jill E. Wood, Holia Hatoum-Mokdad, Jeffrey Johnson, Wendy Lee, Aniko Redman, Robert Sibley, Joel Renick
  • INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
    Publication number: 20120046290
    Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.
    Type: Application
    Filed: October 31, 2007
    Publication date: February 23, 2012
    Inventors: Jacques Dumas, Uday Khire, Timothy B. Lowinger, Holger Paulsen, Bernd Riedl, William J. Scott, Roger A. Smith, Jill Wood, Holia Hatoum-Mokdad, Wendy Lee, Aniko Redman, Jeffrey Johnson, Robert Sibley
  • Rho kinase inhibitors
    Patent number: 8093266
    Abstract: Substituted amide and urea derivatives useful as inhibitors of Rho kinase are described, which inhibitors can be useful in the treatment of various disorders such as cardiovascular diseases, cancer, neurological diseases, renal diseases, bronchial asthma, erectile dysfunction and glaucoma.
    Type: Grant
    Filed: January 2, 2008
    Date of Patent: January 10, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Georg Dahmann, Eugene Richard Hickey, Xiang Li, Wang Mao, Daniel R. Marshall, Tina M. Morwick, Robert Sibley, Roger John Snow, Ronald J. Sorcek, Frank Wu, Erick Richard Roush Young
  • RHO KINASE INHIBITORS
    Publication number: 20100041645
    Abstract: Substituted amide and urea derivatives useful as inhibitors of Rho kinase are described, which inhibitors can be useful in the treatment of various disorders such as cardiovascular diseases, cancer, neurological diseases, renal diseases, bronchial asthma, erectile dysfunction and glaucoma.
    Type: Application
    Filed: January 2, 2008
    Publication date: February 18, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Georg Dahmann, Eugene Richard Hickey, Xiang Li, Wang Mao, Daniel R. Marshall, Tina M. Morwick, Robert Sibley, Roger John Snow, Ronald J. Sorcek, Frank Wu, Erick Richard Roush Young
  • Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
    Patent number: 7625915
    Abstract: Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: December 1, 2009
    Assignee: Bayer HealthCare LLC
    Inventors: Jacques Dumas, Uday Khire, Timothy B. Lowinger, Bernard Riedl, William J. Scott, Roger A. Smith, Jill E. Wood, Holia Hatoum-Mokdad, Jeffrey Johnson, Aniko Redman, Robert Sibley
  • Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
    Patent number: 7517880
    Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: April 14, 2009
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Scott Miller, Martin Osterhout, Jacques Dumas, Uday Khire, Timothy B. Lowinger, William J. Scott, Roger A. Smith, Jill E. Wood, David E. Gunn, Holia Hatoum-Mokdad, Marell Rodriguez, Robert Sibley, Ming Wang, Tiffany Turner, Catherine Brennan